Some Diabetics at Higher Risk for Heart Disease
Posted on: Thursday, 4 December 2008, 08:16 CST
The combination of genetics and glycemic control may make some diabetics more likely to have heart disease.A new report from Harvard Medical School finds patients with type 2 diabetes who have poor glycemic control and a certain genetic variation are more at risk of coronary artery disease (CAD).
Genetic variation on chromosome 9p21 has been associated with increased risk of CAD in the general population. Researchers wanted to know how it affected type 2 diabetics and whether poor glycemic control made a difference. They conducted two studies -- one included 734 patients with type 2 diabetes patients, 322 with CAD; 412 without . The other study had 475 patients with type 2 diabetes whose survival was monitored during the trial.
Results show the odds for CAD in patients with two risk gene variants but not poor glycemic control was increased two-fold while the odds for CAD among those with the same genotype but poor glycemic control was increased four-fold. The interaction was stronger when a measure of long-term glycemic control was used in patients with two risk gene variants and a history of poor glycemia and for those with the same genotype but not long-term poor glycemia.
There was also a similar interaction between the 9p21 variant and poor glycemic control with respect to the rate of death after 10 years.
The authors conclude, the 9p21 variant and poor glycemic control interact in determining the odds of CAD in type 2 diabetes. They say this finding may lead to a better understanding of how plaque forms in the arteries of diabetics and could help lead to better ways to prevent it.
-----
On The Net:
Ivanhoe
Related Articles
- Diabetes Experts Recommend One-Two Punch for Treating Patients With Pre-Diabetes
- VAP Test Helps Researchers Uncover Best Cholesterol Lowering Treatment for Type II Diabetes
- Eucreas Recommended for EU Approval for Type II Diabetes
- Isis Starts Study of Type II Diabetes Drug
- Vernalis Plc Initiates a Phase I Trial of a Promising New Approach to Treating Obesity and Related Disorders - Including Type II Diabetes
- Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial of Testim(R) in Patients With Type II Diabetes
- Depomed Data Published in Diabetes Care on Glumetza, an FDA-Approved Treatment for Type II Diabetes
- Call for Participants: Type II Diabetes Research Subjects Needed
- Oral Meds Good for Controlling Type II Diabetes in Children
- Managing Type II Diabetes Sharply Cuts Heart Risk
User Comments (0)

RSS Feeds